Mahoney, Kathleen M. http://orcid.org/0000-0002-3869-6803
Shukla, Sachet A. http://orcid.org/0000-0003-2445-3584
Patsoukis, Nikolaos http://orcid.org/0000-0001-8746-5692
Chaudhri, Apoorvi http://orcid.org/0000-0002-8785-234X
Browne, Edward P. http://orcid.org/0000-0001-9070-7015
Arazi, Arnon
Eisenhaure, Thomas M. http://orcid.org/0000-0003-3999-3540
Pendergraft, William F. III
Hua, Ping
Pham, Hung C.
Bu, Xia
Zhu, Baogong
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Fritsch, Edward F.
Boussiotis, Vassiliki A. http://orcid.org/0000-0002-3963-1518
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Freeman, Gordon J. http://orcid.org/0000-0002-7210-5616
Funding for this research was provided by:
DF/HCC Kidney Cancer SPORE (P50CA101942, P50CA101942)
Claudia Adams Barr Program for Innovative Cancer Research
2014 AACR Basic Cancer Research Fellowship (14-40-01-MAHO)
2014 ASCO Young Investigator Award supported by Kidney Cancer Association
Article History
Received: 25 May 2018
Accepted: 2 December 2018
First Online: 18 December 2018
Conflict of interest
: Shukla has equity in 152 Therapeutics. Freeman and Boussiotis have patents/pending royalties on the PD-1 pathway from Bristol-Myers-Squibb, Roche, Merck, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Dako, and Novartis. Freeman has a patent application for the use of 9A11 antibody for diagnostic purposes. Hacohen and Wu are founders of Neon Therapeutics and members of its scientific advisory board. Patent applications have been filed: Compositions and Methods for Personalized Neoplasia Vaccines (Hacohen, Fritsch, and Wu), Methods for Identifying Tumor Specific Neo-Antigens (Hacohen and Wu), and Combination Therapy for Neoantigen Vaccine (Hacohen, Wu, and Fritsch). Fritsch is a co-founder and employee of Neon Therapeutics, Inc. All other authors declare that they have no conflict of interest.
: The protocol (#13-3774) for the sequencing of sorted peripheral blood cells from normal healthy donors was passed by the University of North Carolina’s Internal Review Board; donors signed informed consent. The protocol #93-011, (B7 Costimulation Protocol (The Role of PD-1 Ligand in Immune Evasion by Breast Cancer)) for the use for collection of blood from healthy donors was passed by the Dana-Farber/Harvard Cancer Center’s Internal Review Board for the use in lymphocyte activation assays; informed consent was waived as donors are anonymous and cannot be identified.
: HDLM2, L428, OC1-LY1 hematologic cell lines were a gift of Dr. Margaret Shipp [CitationRef removed]. Kidney cancer cell lines (Caki-2, 769-P, SN12C, UMRC6) were a gift of Drs. Chuan Shen and William Kaelin. MDA-MB-231, SKBR3, and BT474 were obtained from American Type Culture Collection (ATCC). Adherent epithelial cell lines (renal and breast lines) were passed by trypsinization; for flow cytometry, adherent cells were detached from plastic with 1 mM EDTA-PBS to minimize cleavage of extracellular protein domains for authentification by cell-surface markers. Lymphoid and kidney cell lines were authenticated by expression of cell-surface lineage markers. Cell lines from ATCC were authenticated at ATCC by STR profiling and maintained in culture for less than 6 months.